A recent study published in the Journal of Infectious Disease confirmed that a vaccine study halted in 2007 showed an increased risk of infection in the first 18 months for subgroups of the men who were vaccinated, but that this difference disappeared after 18 months.
While vaccines against Streptococcus pneumoniae have cut the number of deaths from this bug that can cause pneumonia and meningitis, the number of cases has tripled in the past 50 years.
Japan has granted marketing approval for its first inactivated polio vaccine (IPV), Sanofi's Imovax Polio, and will begin using the vaccine in public immunization programs beginning Sept. 1.
GlaxoSmithKline's meningitis vaccine Nimenrix has been granted approval in Europe by the Committee for Medicinal Products for Human Use (CHMP).
The World Health Organization has declared this week to be World Immunization Week.
In Nigeria, around 3.3 million people were living with HIV/AIDS in 2010. To try to combat this, the country is kick-starting its vaccine program again.
Researchers in the U.S. and Australia have found that salmonella bacteria have the capacity to overwhelm vaccines.
Taiwanese researchers are developing a virus-based RSV vaccine that could complete preclinical studies next year, and has already shown signs of efficacy.
There are no dengue virus vaccines so far, but new research from the University of North Carolina and Vanderbilt University could help speed vaccines to the market.
The Thai trial, also known as RV144, was published in the NEJM in 2009 and is the subject of a new study, which has tried to unpack just how that protective effect worked.